Related by context. All words. (Click for frequent words.) 69 comparators 56 active comparator 54 comparator arm 54 #:# randomization 53 oral diclofenac 53 ritonavir boosted 52 LPV r 52 non inferiority 52 noninferiority 52 melphalan prednisone 51 ABC/3TC 51 mg kg dose 51 eplerenone 51 Protelos 51 dabigatran etexilate 51 placebo 51 tipranavir 51 Taxotere ® 51 lopinavir r 51 irbesartan 51 #mg dose [001] 50 multicentre randomized 50 insulin glargine 50 unfractionated heparin 50 bivalirudin 50 iodixanol 50 adalimumab 50 peginterferon alfa 2b 50 prespecified 50 comparator PI r 50 atazanavir ritonavir 50 unfractionated heparin UFH 50 RE LY ® 50 pegylated interferon alfa 2b 50 mg dose 50 dexmedetomidine 50 low dose cytarabine 50 gadobutrol 50 mg QD 50 subcutaneously administered 50 prospectively defined 49 topotecan 49 TMC# r 49 sirolimus eluting stent 49 CIMZIA TM 49 darbepoetin alfa 49 Navelbine 49 certolizumab 49 mg BID 49 dose cytarabine 49 oral antidiabetic 49 chlorambucil 49 temsirolimus 49 tapentadol ER 49 TNF inhibitor 49 monotherapy 49 5-FU/LV 49 docetaxel 49 mcg doses 49 TPV r 49 Epirubicin 49 seroprotection 49 dacarbazine 49 idraparinux 49 achieved statistical significance 49 multicenter randomized placebo controlled 48 DMARD 48 ARB telmisartan 48 tecarfarin 48 pharmacokinetics PK 48 #mg BID [003] 48 ancrod 48 cobicistat 48 GP IIb IIIa inhibitor 48 desvenlafaxine succinate 48 XELOX 48 palonosetron 48 multicenter randomized 48 animal xenograft models 48 glargine 48 reboxetine 48 carboplatin paclitaxel 48 Aptivus ® 48 Peg IFN 48 Fludara 48 CsA 48 paclitaxel carboplatin 48 darunavir ritonavir 48 fludarabine 48 intravenous dosing 48 enoxaparin 48 noninferior 48 antithrombotic 48 insulin detemir 48 aflibercept 48 MoxDuo IR 48 pharmacokinetic equivalence 48 insulin lispro 48 bolus dose 48 randomized 48 budesonide 48 TAVR 48 #mg/day [001] 48 MIRCERA 48 randomized multicenter 48 Cmax 48 tocilizumab 48 efavirenz EFV 48 PREZISTA ritonavir 48 EURIDIS 48 TMC# [001] 48 Visipaque 48 lopinavir ritonavir 48 fondaparinux 48 temozolomide 48 carboplatin 48 FOLFOX 48 #mg/kg [002] 48 imipenem 48 virologic failure 48 abacavir lamivudine 48 tapentadol IR 48 definite stent thrombosis 48 controlled multicenter 48 endoscopic remission 48 piperacillin tazobactam 48 boosted protease inhibitor 48 nonrandomized 47 teriflunomide 47 peginterferon alfa 2a 47 Elitek 47 lumiracoxib 47 composite endpoint 47 darunavir r 47 XGEVA 47 pazopanib 47 CIMZIA TM certolizumab pegol 47 analgesic efficacy 47 Engerix B 47 methotrexate monotherapy 47 glatiramer acetate 47 eribulin mesylate 47 randomized multicentre 47 salmeterol fluticasone 47 levofloxacin 47 TNF alpha inhibitor 47 linezolid 47 CANCIDAS 47 Doxil ® 47 antithrombotics 47 HBeAg seroconversion 47 biphasic insulin aspart 47 lispro 47 Pemetrexed 47 MoxDuo 47 Dabigatran etexilate 47 pegylated interferons 47 statistically significant differences 47 DAS# remission 47 salmeterol fluticasone propionate 47 secondary efficacy endpoint 47 TORISEL 47 oxycodone CR 47 PREZISTA r 47 tobramycin 47 Carvedilol 47 trials RCTs 47 clinically meaningful differences 47 ticagrelor 47 ivabradine 47 Sanofi Aventis Taxotere 47 mcg Albuferon 47 pharmacodynamic properties 47 Emselex 47 MoxDuo TM IR 47 viral kinetics 47 MabCampath 47 serum phosphorus 47 5FU 47 intermittent dosing 47 pharmacokinetic characteristics 47 trabectedin 47 APTIVUS r 47 subcutaneous SC 47 levetiracetam 47 PegIFN 47 TAXUS Stent 47 titrated glipizide 47 saline placebo 47 SVR# 47 sunitinib 47 fluoropyrimidine 47 mg ustekinumab 47 relapsing multiple sclerosis 47 #mg dose [003] 47 dose regimens 47 leuprorelin 47 pharmacokinetic profiles 47 plasma renin activity 47 FOLFIRI 47 dalteparin 47 tamsulosin 47 BEACOPP 47 surrogate endpoint 47 vinorelbine 47 Desferal 47 venlafaxine XR 47 NRTI 47 QT QTc 47 tipranavir r 47 divalproex sodium 47 interferon alfa 47 esomeprazole 46 abatacept 46 thromboprophylaxis 46 epoetin alfa 46 anti TNF 46 Pred Forte 46 CYPHER Stent 46 pioglitazone 46 retapamulin 46 Androgel R 46 endoscopic gastric ulcers 46 atazanavir 46 attain statistical significance 46 tacrolimus ointment 46 synchronous rectifier 46 dose dexamethasone 46 eluting stent 46 median PFS 46 adjunctive placebo 46 #mg doses [002] 46 Faslodex 46 placebo controlled dose escalation 46 pegylated interferon alfa 46 fulvestrant 46 PREZISTA rtv 46 infliximab 46 apremilast 46 baseline HbA1c 46 FFNS 46 ILUVIEN 46 Torisel 46 carvedilol 46 becaplermin 46 Pharmacokinetic studies 46 sirolimus eluting 46 chlorthalidone 46 decitabine 46 evaluable 46 multicenter multinational 46 HMG CoA reductase inhibitor 46 dose titration 46 enalapril 46 mcg albinterferon alfa 2b 46 lacosamide 46 rilpivirine 46 ANCHOR trial 46 IOP lowering 46 glimepiride 46 vancomycin 46 L PPDS 46 antihyperglycemic 46 vicriviroc 46 sitagliptin 46 LCP AtorFen 46 Randomized Evaluation 46 etanercept 46 antiarrhythmic 46 CR nPR 46 fibrinolytic 46 atorvastatin #mg 46 placebo controlled clinical trials 46 microg 46 gp# vaccine 46 clodronate 46 ug kg 46 timolol 46 IFN alfa 46 tiotropium 46 pharmacodynamic endpoints 46 posaconazole 46 rFVIIa 46 Humalog ® 46 IFN α 46 doripenem 46 Mimpara 46 goserelin 46 randomization 46 strontium ranelate 46 FOLFOX4 46 factor Xa inhibitor 46 Q2W 46 administered subcutaneously 46 randomisation 46 prospective multicenter randomized 46 Capecitabine 46 intravenous cyclophosphamide 46 interferon beta 1b 46 mitomycin 46 stent binary restenosis 46 BARACLUDE r 46 NOXAFIL Oral Suspension 46 oral rivaroxaban 46 febuxostat 46 cisplatin vinorelbine 46 Histalean TM 46 CIMZIA ™ 46 blind placebo 46 IELT 46 rHuEPO 46 placebo dexamethasone 46 virologic response 45 tirofiban 45 NovoTTF 45 #mg QD [002] 45 tolerability 45 pharmacodynamics 45 systemic absorption 45 randomized blinded 45 mmol l 45 glulisine 45 dihydropyridine 45 Baseline characteristics 45 fluticasone 45 dosage regimens 45 NPH insulin 45 MoxDuo ® IR 45 CRp 45 efficacy endpoint 45 prospective randomized multicenter 45 mcg kg 45 eptifibatide 45 ACCORD Lipid 45 evaluable patients 45 pain palliation 45 Betaferon ® 45 degarelix 45 ISENTRESS 45 argatroban 45 peg IFN 45 fluorouracil 45 Omiganan 45 clomipramine 45 #μg [002] 45 Kivexa 45 everolimus eluting stent 45 rFSH 45 pegylated interferon alpha 45 PEG Intron 45 mycophenolate mofetil 45 sirolimus stent 45 logistic regression analysis 45 Taxus Stent 45 bicalutamide 45 pramlintide metreleptin combination 45 Fulvestrant 45 comparator PI 45 IFN beta 45 therapeutic equivalence 45 zopiclone 45 mg qd 45 JANUVIA 45 secondary endpoint 45 enfuvirtide 45 PegIFN RBV 45 Randomised 45 Androgel 45 glufosfamide 45 interferon alfa 2b 45 lanthanum carbonate 45 factorial design 45 5mg 45 glycoprotein IIb IIIa inhibitor 45 #mg BID [002] 45 ranolazine 45 ULORIC 45 peginterferon 45 Pegasys ® 45 nadolol 45 leukocyte count 45 clobazam 45 gemcitabine carboplatin 45 locoregional disease 45 antiresorptive 45 Platinol 45 oxycodone IR 45 plus prednisone 45 doxorubicin docetaxel 45 multicentre randomized double 45 statistical significance 45 intratumoral injection 45 Kaplan Meier analysis 45 pharmacokinetic parameters 45 ENDOMETRIN 45 DU #b 45 TRITON TIMI 45 intradermal injection 45 deferoxamine 45 ZACTIMA 45 secondary efficacy endpoints 45 dose dose escalation 45 mg/m2 dose 45 DAPT 45 Rituxan MabThera 45 tenofovir emtricitabine 45 QRS duration 45 XIENCE V PROMUS Stent 45 pharmacodynamics PD 45 multicenter Phase II 45 liposomal doxorubicin 45 ARCOXIA 45 oral Hycamtin 45 recurrent GBM 45 Omacetaxine mepesuccinate 45 p = #.# [002] 45 zoledronic acid 45 Lovaza ® 45 tigecycline 45 TELCYTA 45 crossclamp 45 PASI scores 45 Crestor rosuvastatin 45 mcg BID 45 rizatriptan 45 pCR 45 APTIVUS 45 estramustine 45 Interferon alfa 45 CHAMPION PCI 45 cinacalcet 45 Roche Xeloda 45 efficacy 45 #mg dosing 45 docetaxel chemotherapy 45 #mg QD [001] 45 plasma concentrations 45 platelet inhibitor 45 irinotecan 45 FOLPI 45 QVAR R 45 Cytoxan 45 efficacy endpoints 45 octreotide LAR 45 subcutaneous dosing 45 rapid virologic response 45 bolus injection 45 ARIXTRA 45 favorable tolerability 45 nateglinide 45 bovine thrombin 45 Telmisartan 45 n = 45 povidone iodine 45 sitagliptin Januvia 45 zonisamide SR 45 chemoradiotherapy 45 timepoints 45 FDA defined valvulopathy 45 patients evaluable 45 lopinavir r arm 45 Tarceva TM 45 rhGH 45 mitoxantrone 45 gemcitabine 45 bortezomib 45 NOXAFIL 45 Q#IR 45 ximelagatran 45 seroconversion 45 telbivudine 45 ascending dose 45 pulse width modulation PWM 45 multicenter randomized controlled 45 sulphonylureas 45 mTOR inhibitors 45 mepolizumab 45 daunorubicin 45 TYGACIL 45 mITT population 45 plus ribavirin 44 intravenous diuretics 44 anti arrhythmic 44 migalastat HCl 44 multicentre 44 Nanobodies 44 5 FU 44 AST ALT 44 randomized #:# 44 pegylated liposomal doxorubicin 44 prospectively randomized 44 bendamustine 44 epoetin 44 TEAEs 44 nab paclitaxel 44 Taxotere 44 logistic regression models 44 ADAGIO study 44 oral antidiabetes drugs 44 mg clopidogrel 44 events AEs 44 DACH platinum 44 unboosted 44 primary patency 44 Coversyl 44 ENGAGE AF TIMI 44 anti leukemic 44 avosentan 44 QTc prolongation 44 cardiovascular calcification 44 cetuximab 44 randomized placebo controlled 44 mecamylamine 44 MoxDuo ® 44 #ug [001] 44 Resolute DES 44 dimeglumine 44 Exforge HCT 44 plus dexamethasone 44 progression TTP 44 intravenous IV infusion 44 RLAI 44 LEXIVA r 44 beta blocker metoprolol 44 plus gemcitabine 44 dosing intervals 44 fluticasone salmeterol 44 Zentase 44 gefitinib 44 abciximab 44 basal insulin 44 nondiabetic patients 44 Taxol ® 44 sustained virologic response 44 SCH # 44 nilotinib 44 primary endpoint 44 Free Survival PFS 44 reteplase 44 IIIa inhibitors 44 GAMMAGARD 44 SIR Spheres 44 lapatinib 44 LTRA 44 hematologic toxicity 44 placebo controlled randomized 44 BoNTA 44 ToGA 44 INTELENCE 44 mcg dose 44 free survival PFS 44 NATRECOR R 44 ketorolac 44 oblimersen 44 bivalirudin monotherapy 44 erythropoietic 44 univariate 44 selective receptor agonist 44 DepoDur TM 44 galiximab 44 zonisamide 44 amphotericin 44 mRCC 44 discontinuations due 44 ADL# 44 ATACAND 44 sorafenib Nexavar 44 metformin monotherapy 44 elvitegravir 44 Comparator 44 ziprasidone 44 tolerability profiles 44 biphasic insulin 44 darunavir 44 pomalidomide 44 dosing 44 fluvastatin 44 intramuscular IM 44 Arixtra 44 pharmacologically active isomer 44 placebo fluoxetine 44 nonfatal MI 44 tolerability profile 44 mesalazine 44 amlodipine 44 CYPHER ® Stent 44 FIRAZYR 44 rosuvastatin 44 ACR# response 44 thromboembolic events 44 glatiramer acetate Copaxone 44 PEGylated interferon beta 1a 44 latanoprost 44 oral olanzapine 44 monoclonal anti 44 adefovir 44 factor Xa 44 EBRT 44 prospective multicenter 44 multivariable logistic regression 44 desvenlafaxine 44 serum IGF 44 Viramune ® 44 label dose titration 44 non squamous histology 44 multicenter prospective 44 ADAS cog 44 elotuzumab 44 A1c levels 44 glycated hemoglobin levels 44 subgroup analyzes 44 DexaSite 44 blinded randomized controlled 44 Erlotinib 44 vidofludimus 44 Gatifloxacin 44 CERVARIX 44 cells mcL 44 prednisone prednisolone plus 44 protease inhibitor PI 44 STN stimulation 44 dacarbazine chemotherapy 44 anastrozole 44 anti TNFs 44 insulin glulisine 44 amprenavir 44 chemotherapy docetaxel 44 Phase III randomized 44 erlotinib 44 EndoTAG TM -1 44 antimuscarinic 44 azathioprine 44 multivariable analysis 44 univariate analysis 44 mg subcutaneously 44 landmark ATHENA 44 plasma glucose 44 mg subcutaneous 44 mg kg 44 dosing regimen 44 bioequivalent 44 IV DHE 44 oxaliplatin 44 plus COPEGUS 44 beclomethasone dipropionate 44 NXL# 44 Takeda Actos 44 iniparib 44 UCB Keppra 44 thorough QT 44 glycoprotein IIb IIIa inhibitors 44 olmesartan 44 levosimendan 44 HCV RESPOND 2 44 granisetron 44 multivariate analyzes 44 seliciclib 44 prucalopride 44 experienced virologic failure 44 antiviral efficacy 44 binary restenosis 44 peginterferon alpha 2a 44 Navelbine ® 44 maximal dose 44 Lantus R 44 MedTone inhaler 44 fluticasone propionate FP 44 micafungin 44 VELCADE melphalan 44 bezafibrate 44 ASTEROID 44 Femara letrozole 44 xanthine oxidase inhibitor 44 P = .# 44 lispro alone 44 remifentanil 44 ritonavir boosted lopinavir 44 NeoRecormon 44 Hycamtin 44 relapsed CLL 44 Ixempra 44 prednisolone acetate 44 eprodisate Fibrillex TM 44 bacillus Calmette Guerin 44 dermaPACE TM 44 cilostazol 44 Roche Pegasys 44 Apidra ® 44 vernakalant hydrochloride 44 receptor blocker 44 multicenter randomized double 44 Entocort EC 44 overlapping toxicities 44 triamcinolone 44 repaglinide 44 IIIa inhibitor 44 statistically significant improvement 44 Lantus insulin 44 carbidopa levodopa 44 RoACTEMRA 44 needleless IV connector 44 sorafenib 44 creatinine clearance 44 interferon alpha 2a 44 adverse cytogenetics 44 guanfacine 44 Rezular 44 anti resorptive 44 neurologic progression 44 atrasentan 44 alteplase 44 doxazosin 44 double blinded randomized 44 rHuPH# 44 crizotinib PF # 44 immunosuppressant 44 MMX mesalamine 44 FOLFIRI alone 44 efficacy tolerability 44 antibody titer 44 thienopyridine 44 bleomycin 44 prospective randomized 44 blind randomized 44 simvastatin ezetimibe 44 NEVO ™ 44 ROCKET AF 44 aspirin clopidogrel 44 teriparatide 44 Epivir HBV 44 TDF FTC 44 EmbraceAC 44 alendronate 44 oral ribavirin 44 Hazard Ratio 44 Xanafide 44 p = #.# [004] 44 nonobese 44 capecitabine 44 Prograf ® 44 antiretroviral naïve 44 Taxotere R 44 mcg QD 44 FOSRENOL ® 44 ciclosporin 44 viral kinetic 44 HbA 1c levels 44 serologically active patients 44 regorafenib 44 symptomatic VTE 44 bisoprolol 44 valsartan 44 stavudine d4T 44 tenecteplase 43 interferon alpha 43 doxorubicin cyclophosphamide 43 Tyrima 43 diuretic chlorthalidone 43 mcg mL 43 LIPUS 43 gemcitabine cisplatin 43 hypoglycemic events 43 AstraZeneca Toprol XL 43 genotypic resistance 43 Eligen R B# 43 vandetanib 43 dose escalation 43 pantoprazole 43 bosentan 43 trastuzumab 43 VIAject ™ 43 CCyR 43 Phase III randomized controlled 43 MMSE score 43 M6G 43 bupropion SR 43 PEG IFN 43 low dose dexamethasone 43 concurrent chemoradiation 43 Betaseron ® 43 fostamatinib 43 Kaletra lopinavir ritonavir 43 EDEMA3 43 LMWH 43 DLTs 43 dose cyclophosphamide 43 selegiline 43 μg kg 43 Cloretazine 43 urinary N telopeptide 43 relapsed ovarian cancer 43 Pegasys 43 low dose ritonavir 43 metabolic parameters 43 erection hardness 43 VAPRISOL 43 estimated GFR 43 escitalopram 43 reactogenicity 43 Darunavir 43 SNRI 43 demonstrated clinically meaningful 43 urate lowering 43 CAELYX 43 HCV SPRINT 43 g dL 43 ritonavir boosted atazanavir 43 flutamide 43 plus methotrexate 43 gastric pH 43 pharmacodynamic 43 Phase IIIb 43 logistic regression analyzes 43 melphalan 43 gliclazide 43 Butrans 43 monotherapies 43 Sprague Dawley rats 43 Epivir 43 nucleoside reverse transcriptase inhibitor 43 qd 43 HbA1C levels 43 percutaneous injection 43 RezularTM 43 Ereska 43 dosing regimens 43 statistically significant p = 43 Metvix 43 statistically significant 43 events MACE 43 intravenously administered 43 IV bisphosphonates 43 Lucentis monotherapy 43 rhEPO 43 cefepime 43 doxorubicin HCl liposome injection 43 pharmacokinetic profile 43 multicenter clinical 43 revascularizations 43 transaminase elevations 43 etanercept Enbrel 43 Zocor simvastatin 43 lamivudine 43 periprocedural 43 cytotoxic chemotherapy 43 4mg/kg 43 pretreatment baseline 43 Noxafil 43 antiarrhythmic drug 43 non selective NSAIDs 43 randomized multicenter trial 43 ALVESCO 43 complete cytogenetic response 43 biologic DMARD 43 oxcarbazepine 43 Pioglitazone 43 LH RH 43 subanalysis 43 GPIIb IIIa inhibitors 43 label multicenter 43 Randomized controlled 43 telaprevir dosed 43 dose Iluvien 43 continuous intravenous infusion 43 PegIntron 43 Irinotecan 43 Trizivir 43 HOMA IR 43 mTOR inhibitor 43 intratympanic 43 thrombin inhibitors 43 sustained virological response 43 omalizumab 43 BENICAR 43 paricalcitol 43 sodium nitroprusside 43 SRT# [003] 43 sleeve lobectomy 43 ezetimibe simvastatin 43 Comparators 43 Benchmarked 43 placebo p = 43 mg sumatriptan 43 fosamprenavir 43 STELARA 43 venlafaxine 43 adjuvant tamoxifen 43 histologies 43 ovulation suppression 43 REMINYL ® 43 Telzir 43 Genasense 43 Anticalins ® 43 Amrubicin 43 tertile 43 TMP SMX 43 Phase 1b clinical 43 nelfinavir 43 sevelamer carbonate 43 salmeterol 43 neostigmine 43 YERVOY 43 epoprostenol 43 leucovorin 43 nicardipine 43 Eloxatin R 43 prulifloxacin 43 TAXOTERE R 43 rivaroxaban 43 TURBT 43 Movectro 43 pegylated interferon 43 GP IIb IIIa inhibitors 43 HCV genotype 43 adalimumab Humira 43 eszopiclone 43 aprepitant 43 neoadjuvant 43 parecoxib 43 FOLFOX regimen 43 isoproterenol 43 abacavir 43 postoperative chemotherapy 43 PSD# 43 albumin excretion rate 43 #mg/m# [002] 43 adenosine injection 43 intravesical 43 randomized #:#:# 43 olmesartan medoxomil 43 randomized controlled 43 felodipine 43 locoregional recurrence 43 injectable formulations 43 pioglitazone Actos 43 fluvoxamine 43 pharmacodynamic PD 43 ICSs 43 anti tumor necrosis 43 Subgroup analysis 43 postintervention 43 SCr 43 nucleoside naive patients 43 Hycamtin ® 43 Non inferiority 43 Zortress 43 MADRS score 43 #mg dose [002] 43 sirolimus eluting stents 43 Gemcitabine 43 oral deforolimus 43 idarubicin 43 randomized crossover 43 multicenter randomized clinical 43 prospective randomized controlled 43 relapsed SCLC 43 ACEI ARB 43 COPEGUS 43 pegnivacogin 43 Ceplene/IL-2 43 null hypothesis 43 mg Lucentis 43 coadministration 43 vaginal brachytherapy 43 PREVENT IV 43 clevidipine 43 paliperidone ER 43 anastrazole 43 olanzapine 43 adriamycin 43 drotrecogin alfa activated 43 prospective randomized placebo 43 Orazol 43 DOXIL 43 ANOVA 43 PRIMO CABG 43 dose colchicine 43 valacyclovir 43 everolimus 43 ketoconazole 43 briakinumab 43 heavily pretreated 43 Adverse events 43 pharmacokinetic interactions 43 serum concentrations 43 subcutaneous insulin 43 macrolide antibiotic 43 oral anticoagulant 43 zidovudine lamivudine 43 pharmacodynamic profile 43 refractory metastatic colorectal cancer 43 postprandial glycemia 43 systemic embolism 43 Kaplan Meier estimate 43 LIALDA 43 % CI #.#-#.# [006] 43 PrevOnco ™ 43 oxaliplatin Eloxatin 43 dose escalation trial